endocrinology
Bone health

Decade of denosumab data shows consistent safety profile

Denosumab treatment for up to 10 years is associated with a persistent reduction of bone turnover, continued increases in bone mineral density and a low incidence of fractures in postmenopausal women with osteoporosis, according to new data from the FREEDOM Extension trial. Dr Henry G Bone III, MD, from the Michigan Bone and Mineral Clinic, in ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic